Categories
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (VBI) today announced that Jeff Baxter, President and CEO, will provide a corporate overview and update at two investor conferences in September. VBI will present at the Cantor Fitzgerald Global Healthcare Conference at...
Read More
Sci-B-Vac® is a third-generation hepatitis B vaccine, approved for use in Israel and 14 other countries VBI expects to initiate enrollment in a Phase 3 clinical program later in the second half of 2017 in the U.S., Europe and Canada...
Read More
IND-enabling data, including restimulation of CMV-specific T-cell immunity in Rhesus Macaques Mechanistic data demonstrating VBI-1901 stimulates innate immunity Data presentation Wednesday, August 30, 2017 VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (VBI), today announced that David Anderson, Ph.D., Chief Scientific...
Read More
VBI-1901 is a novel immunotherapy developed using VBI’s eVLP technology On track to initiate a Phase 1/2a clinical study in the second half of 2017 VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious...
Read More
Well tolerated at all doses with no safety signals 100% seroconversion at highest dose after two of the three planned vaccinations Dose-dependent antibody responses against CMV gB antigen Full data after third dose expected first half of 2018 Conference Call...
Read More
Replay Webcast VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) announced today its plans for a global Phase 3 clinical program for Sci-B-Vac®, its third-generation hepatitis B vaccine, following positive discussions with the U.S. Food & Drug Administration (FDA), the...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) today announced the voting results from its annual general and special meeting (the “Meeting”) held on June 22, 2017. 30,823,557 common shares were represented at the Meeting, totaling 76.94% of VBI issued and...
Read More
VBI Vaccines, Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, announced today that it has been added to the Russell 2000® and the Russell 3000® Indexes following the annual reconstitution, which...
Read More
Media Contact
Perri Maduri, Communications Executive
Telephone: (617) 830-3031 x124
Email: ir@vbivaccines.com